Bovine serum albumin nanoparticles containing Poly (I:C) can enhance the neutralizing antibody response induced by envelope protein of Orthoflavivirus zikaense

[Display omitted] •BSA nanoparticles containing Poly(I:C) were produced.•These nanoparticles induce increase in cellularity after administration in mice skin.•Mice immunized with zEDIII and nanoparticles show higher production of antibodies.•These antibodies show in vitro and in vivo neutralizing ac...

Full description

Saved in:

Bibliographic Details
Published in:	International immunopharmacology Vol. 128; p. 111523
Main Authors:	Piva-Amaral, Raíne, Augusto Pires de Souza, Gabriel, Carlos Vilela Vieira Júnior, João, Fróes Goulart de Castro, Renato, Permagnani Gozzi, William, Pereira Lima Neto, Sergio, Cauvilla dos Santos, Ana Luisa, Pavani Cassiano, Helena, Christine Ferreira da Silva, Lorena, Dias Novaes, Romulo, Santos Abrahão, Jônatas, Ervolino de Oliveira, Carine, de Mello Silva, Breno, de Paula Costa, Guilherme, Cosme Cotta Malaquias, Luiz, Felipe Leomil Coelho, Luiz
Format:	Journal Article
Language:	English
Published:	Netherlands Elsevier B.V 15-02-2024
Subjects:	Adjuvant Albumin Nanoparticles Poly (I:C) Zika virus Nanoparticles Albumin Adjuvant Poly (I:C) Zika virus
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	[Display omitted] •BSA nanoparticles containing Poly(I:C) were produced.•These nanoparticles induce increase in cellularity after administration in mice skin.•Mice immunized with zEDIII and nanoparticles show higher production of antibodies.•These antibodies show in vitro and in vivo neutralizing activity. Since the Orthoflavivirus zikaense (ZIKV) has been considered a risk for Zika congenital syndrome development, developing a safe and effective vaccine has become a high priority. Numerous research groups have developed strategies to prevent ZIKV infection and have identified the domain III of the ZIKV envelope protein (zEDIII) as a promising target. Subunit antigens are often poorly immunogenic, necessitating the use of adjuvants and/or delivery systems to induce optimal immune responses. The subject of nanotechnology has substantial expansion in recent years in terms of research and applications. Nanoparticles could be used as drug delivery systems and to increase the immunogenicity and stability of a given antigen. This work aims to characterize and validate the potential of a vaccine formulation composed of domain zEDIII and bovine serum albumin nanoparticles containing polyinosinic-polycytidylic acid (NPPI). NPPI were uptake in vitro by immature bone marrow dendritic cells and histological analysis of the skin of mice treated with NPPI showed an increase in cellularity. Immunization assay showed that mice immunized with zEDIII in the presence of NPPI produced neutralizing antibodies. Through the passive transfer of sera from immunized mice to ZIKV-infected neonatal mice, it was demonstrated that these antibodies provide protection, mitigating weight loss, clinical or neurological signs induced by infection, and significantly increased survival rates. Protection was further substantiated by the reduction in the number of viable infectious ZIKV, as well as a decrease in inflammatory cytokines and tissue alterations in the brains of infected mice. Taken together, data presented in this study shows that NPPI + zEDIII is a promising vaccine candidate for ZIKV.
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	1567-5769 1878-1705
DOI:	10.1016/j.intimp.2024.111523